BIOX vs PGEN

For growth investors, Bioceres Crop Solutions Corp.

(BIOX) is the stronger pick with -28. 3% revenue growth year-over-year, versus -36. 9% for Precigen, Inc. (PGEN). Analysts rate Precigen, Inc. (PGEN) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Precigen, Inc.

(PGEN) delivered a total return of -33. 7%, compared to -96. 8% for Bioceres Crop Solutions Corp. (BIOX). Over 10 years, the gap is even starker: PGEN returned -83. 0% versus BIOX's -95. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Precigen, Inc.

(PGEN) is the lower-risk stock at 1. 44β versus Bioceres Crop Solutions Corp. 's 1. 94β — meaning BIOX is approximately 34% more volatile than PGEN relative to the S&P 500. On balance sheet safety, Precigen, Inc. (PGEN) carries a lower debt/equity ratio of 14% versus 94% for Bioceres Crop Solutions Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bioceres Crop Solutions Corp.

(BIOX) is pulling ahead at -28. 3% versus -36. 9% for Precigen, Inc. (PGEN). On earnings-per-share growth, the picture is similar: Precigen, Inc. grew EPS -20. 5% year-over-year, compared to -1704. 7% for Bioceres Crop Solutions Corp.. Over a 3-year CAGR, BIOX leads at 0. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bioceres Crop Solutions Corp.

(BIOX) is the more profitable company, earning -15. 5% net margin versus -32. 2% for Precigen, Inc. — meaning it keeps -15. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BIOX leads at -1. 1% versus -34. 4% for PGEN. At the gross margin level — before operating expenses — BIOX leads at 39. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Precigen, Inc.

(PGEN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Bioceres Crop Solutions Corp. (BIOX) carries a higher beta of 1. 94 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PGEN: -83. 0%, BIOX: -95. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BIOX (Basic Materials) and PGEN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.